• VIDEO: Susvimo shows long-term efficacy in treating wet AMD

    2 monthes ago - By Healio

    CHICAGO - In this Healio Video Perspective, Carl D. Regillo, MD, discusses 3-year follow-up data from the Archway study presented during Retina Subspecialty Day at the AAO meeting.
    The Archway study investigated the Port Delivery System with ranibizumab, now called Susvimo , for the treatment of wet age-related macular degeneration. It showed positive safety and efficacy results in patients who underwent 3 years of follow-up as well as those who underwent 1 year of follow-up in addition to previous intravitreal injections, according to Regillo.
    Read more ...

     

  • VIDEO: Opus Genetics CEO discusses IND application for retinal degeneration gene therapy

    VIDEO: Opus Genetics CEO discusses IND application for retinal degeneration gene therapy

    2 monthes ago - By Healio

    CHICAGO - In this Healio Video Perspective from Eyecelerator AAO, Opus Genetics CEO Ben Yerxa discusses an upcoming investigational new drug application for OPGx-001.
    OPGx-001 is designed to address mutations in the LCA5 gene that cause retinal degeneration.
    “I am excited to see what gene therapy can offer to these kids who really have no other options,” Yerxa said.
    Read more ...